Cognizance Biomarkers is Biotechnology in United States that focus on diagnostic test business. Founded in 2012. They cover business area such as operator, leadership, proteomic and genomic-base testing, improve diagnosis, treatment, neurological disorder, rapid, accurate and cost-effective precision medicine solution, optimal patient outcome, molecule, these inflammation-induce seizure, doctor, people, non-epileptic seizure.
2012
( 12 years old in 2024 )
Diagnostic Test
-
3160 Chestnut Street
Suite 200
Philadelphia, PA 19104
United States
Private
operatorleadershipproteomic and genomic-base testingimprove diagnosistreatmentneurological disorderrapid, accurate and cost-effective precision medicine solutionoptimal patient outcomemoleculethese inflammation-induce seizuredoctorpeoplenon-epileptic seizure
* We use standard office opening hours in near Cognizance Biomarkers's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Cognizance Biomarkers is Biotechnology business from United States that founded in 2012 (12 years old in 2024), Cognizance Biomarkers business is focusing on Diagnostic Test.
Cognizance Biomarkers headquarter office and corporate office address is located in 3160 Chestnut Street Suite 200 Philadelphia, PA 19104 United States.
Cognizance Biomarkers was founded in United States.
In 2024, Cognizance Biomarkers is currently focus on diagnostic test sector.
Above is snippet of Google Trends for "diagnostic test" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Cognizance Biomarkers, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
